RxDoctor Payments Data

Anilkumar Pillai, MD

Internal Medicine · Warner Robins, GANPI 1578519658

Payments from drug & device makers

$63,965in general payments, 2019–2025

Across 380 payments — averaging $168.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$56K
  • Novo Nordisk$1K
  • Amgen$1K
  • AstraZeneca$742
  • Lilly USA, LLC$648
  • Bayer$419
  • plus $4K from 38 others

What the payments were for

  • Grants$56,21988%
  • Food & beverage$7,74612%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,965 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$619,914
Medicare patients
585
Services billed
13,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide142$191,384
EliquisApixaban200$187,013
JardianceEmpagliflozin177$177,531
MounjaroTirzepatide93$144,982
FarxigaDapagliflozin Propanediol120$117,402
OzempicSemaglutide92$116,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$39,595
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl188$38,648
JanuviaSitagliptin Phosphate53$38,546
MyrbetriqMirabegron36$36,995
XareltoRivaroxaban39$32,441
LinzessLinaclotide43$30,364
SuboxoneBuprenorphine Hcl/Naloxone Hcl41$28,355
ArexvyRsvpref3 Antigen/As01e/Pf82$24,389
JanumetSitagliptin Phos/Metformin Hcl18$21,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$648$336,367235 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$256$197,381217 claims
PfizerEliquis$315$187,013200 claims
AstraZenecaFarxiga, Symbicort, Brilinta$742$132,668159 claims
Novo NordiskOzempic$1,163$116,25992 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$270$75,225176 claims
MerckJanuvia, Janumet$111$60,49871 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$14$38,648188 claims
Astellas Pharma US IncMyrbetriq$319$36,99536 claims
Johnson & JohnsonXarelto$270$32,44139 claims
AbbVieLinzess$239$30,36443 claims
Indivior Inc.Suboxone$79$28,35541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →